Drug Approval

Home
About
Help
History (1)
- Drug Approval
- See All Pages

"Drug Approval" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.

Descriptor ID	D017277
MeSH Number(s)	E05.337.300 I01.880.604.605.250.250
Concept/Terms	Drug Approval Drug Approval Approval, Drug Approvals, Drug Drug Approvals Food and Drug Administration Drug Approval Drug Approval Process Drug Approval Process Approval Process, Drug Approval Processes, Drug Drug Approval Processes Process, Drug Approval Processes, Drug Approval New Drug Approval Process New Drug Approval Process New Drug Approval New Drug Approval Approval, New Drug Approvals, New Drug Drug Approval, New Drug Approvals, New New Drug Approvals Food and Drug Administration Drug Approval Process Food and Drug Administration Drug Approval Process

Below are MeSH descriptors whose meaning is more general than "Drug Approval".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Evaluation Studies as Topic [E05.337]
Drug Approval [E05.337.300]
Anthropology, Education, Sociology and Social Phenomena [I]
Social Sciences [I01]
Sociology [I01.880]
Social Control, Formal [I01.880.604]
Legislation, Drug [I01.880.604.605]
Drug and Narcotic Control [I01.880.604.605.250]
Drug Approval [I01.880.604.605.250.250]

Below are MeSH descriptors whose meaning is related to "Drug Approval".

Below are MeSH descriptors whose meaning is more specific than "Drug Approval".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Approval" by people in this website by year, and whether "Drug Approval" was a major or minor topic of these publications.

Bar chart showing 22 publications over 13 distinct years, with a maximum of 3 publications in 2018 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2002	0	1	1
2005	0	1	1
2008	1	0	1
2011	2	0	2
2012	1	1	2
2013	2	0	2
2016	1	1	2
2017	0	2	2
2018	1	2	3
2019	0	1	1
2020	0	1	1
2021	2	1	3

Below are the most recent publications written about "Drug Approval" by people in Profiles.

Vishakha S, Navneesh N, Kurmi BD, Gupta GD, Verma SK, Jain A, Patel P. An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021). Anticancer Agents Med Chem. 2024; 24(8):590-626.

View in: PubMed
Khanna D, Lescoat A, Roofeh D, Bernstein EJ, Kazerooni EA, Roth MD, Martinez F, Flaherty KR, Denton CP. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. Arthritis Rheumatol. 2022 01; 74(1):13-27.

View in: PubMed
Rothschild AJ. Why Is There No Food and Drug Administration-Approved Medication for Major Depression With Psychotic Features? J Clin Psychopharmacol. 2021 Jul-Aug 01; 41(4):359-361.

View in: PubMed
Weiner MW, Aisen PS, Beckett LA, Green RC, Jagust W, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Rivera Mindt M, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ. Editorial: How Will Aducanumab Approval Impact AD Research? J Prev Alzheimers Dis. 2021; 8(4):391-392.

View in: PubMed
Alvarez DF, Wolbink G, Cronenberger C, Orazem J, Kay J. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States? BioDrugs. 2020 Dec; 34(6):723-732.

View in: PubMed
Ollmann Saphire E. A Vaccine against Ebola Virus. Cell. 2020 04 02; 181(1):6.

View in: PubMed
Kaner RJ, Bajwa EK, El-Amine M, Gorina E, Gupta R, Lazarus HM, Luckhardt TR, Mouded M, Posada K, Richeldi L, Stauffer J, Tutuncu A, Martinez FJ. Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies. Am J Respir Crit Care Med. 2019 07 15; 200(2):133-139.

View in: PubMed
Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, Usmani SZ, Londhe A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer. 2018 11 15; 124(22):4342-4349.

View in: PubMed
Huang L, Sang CN, Desai MS. A Chronology for the Identification and Disclosure of Adverse Effects of Succinylcholine. J Anesth Hist. 2019 07; 5(3):65-84.

View in: PubMed
Bridges SL, White DW, Worthing AB, Gravallese EM, O'Dell JR, Nola K, Kay J, Cohen SB. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. Arthritis Rheumatol. 2018 03; 70(3):334-344.

View in: PubMed

People

Explore

Similar Concepts

Top Journals